MD4316B1 - Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis - Google Patents

Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis

Info

Publication number
MD4316B1
MD4316B1 MDA20130063A MD20130063A MD4316B1 MD 4316 B1 MD4316 B1 MD 4316B1 MD A20130063 A MDA20130063 A MD A20130063A MD 20130063 A MD20130063 A MD 20130063A MD 4316 B1 MD4316 B1 MD 4316B1
Authority
MD
Moldova
Prior art keywords
gastropathies
trimethylhydrazinium
patients
liver cirrhosis
propionate dihydrate
Prior art date
Application number
MDA20130063A
Other languages
Moldavian (mo)
Romanian (ro)
Russian (ru)
Other versions
MD4316C1 (en
Inventor
Gheorghe Anghelici
Oleg Crudu
Ulviyya Mammadova
Galina Pavliuc
Original Assignee
Gheorghe Anghelici
Oleg Crudu
Ulviyya Mammadova
Galina Pavliuc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gheorghe Anghelici, Oleg Crudu, Ulviyya Mammadova, Galina Pavliuc filed Critical Gheorghe Anghelici
Priority to MDA20130063A priority Critical patent/MD4316C1/en
Publication of MD4316B1 publication Critical patent/MD4316B1/en
Publication of MD4316C1 publication Critical patent/MD4316C1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, particularly to hepatology.According to the invention, the use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate is claimed for treating portal gastropathies in patients with liver cirrhosis, intravenously, 500 mg, 1…2 times a day, for 7…10 days, then per os, 500 mg, 1…2 times a day, for 4…6 weeks.
MDA20130063A 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis MD4316C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20130063A MD4316C1 (en) 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20130063A MD4316C1 (en) 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis

Publications (2)

Publication Number Publication Date
MD4316B1 true MD4316B1 (en) 2015-01-31
MD4316C1 MD4316C1 (en) 2015-08-31

Family

ID=52440945

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20130063A MD4316C1 (en) 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis

Country Status (1)

Country Link
MD (1) MD4316C1 (en)

Also Published As

Publication number Publication date
MD4316C1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016502352A1 (en) Pharmaceutical composition
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
TW201613578A (en) Pharmaceutical combinations
EA201791110A1 (en) SUBLINGUAL INTRODUCTION OF RHYNESOL
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
EA201790958A1 (en) SUBLINGUAL PREPARATION OF RILUSOL
CO7160080A2 (en) Lipid compositions of racecadot
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
MX367926B (en) Pharmaceutical composition for a sustained release of lanreotide.
MX2016004967A (en) Treatment for pancreatic cancer.
MX2020006075A (en) Bendamustine pharmaceutical compositions.
BR112017002449A2 (en) treatment of symptoms associated with androgen deprivation therapy
MD4317B1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure
MD4316C1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
MD20150017A2 (en) Use of Polybiolin drug in patients with liver cirrhosis
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
UA91605U (en) Method for correcting disordered microcirculation in gastric mucosa of aged patients
IN2014DE00822A (en)
IN2014DE00818A (en)
UA83410U (en) Method for treatment of patients with chronic pancreatitis with ischemic heart disease at congestive heart failure

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees